Abstract | OBJECTIVE: METHODS: This was a five-arm study in two xenograft ovarian cancer mouse models, ES-2 ( platinum-sensitive), and OVCAR3 (platinumresistant), to evaluate the combination of liposomal doxorubicin with the common chemotherapeutic agents. Each cell line had five mice for each treatment arm, five vehicle control mice, and five liposomal doxorubicin alone control mice. Experiments were done in duplicate. RESULTS: The percentage tumor reduction ranged from 52% to 74.1% for the single-agent treatment arms. Tumor growth inhibition and regression (response) was improved on the combination treatment arms ranging from 76.1% to 100%. We observed increased activity in the liposomal doxorubicin plus topotecan arm, with a 27.3% improvement in response, compared with either agent alone. CONCLUSIONS:
|
Authors | Jenifer M Saucier, Jiang Yu, Anjali Gaikwad, Robert L Coleman, Judith K Wolf, Judith A Smith |
Journal | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
(J Oncol Pharm Pract)
Vol. 13
Issue 1
Pg. 39-45
(Mar 2007)
ISSN: 1078-1552 [Print] England |
PMID | 17621566
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibiotics, Antineoplastic
- Antineoplastic Agents
- Liposomes
- Platinum Compounds
- Topotecan
- Doxorubicin
|
Topics |
- Animals
- Antibiotics, Antineoplastic
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology, therapeutic use)
- Disease Models, Animal
- Doxorubicin
(therapeutic use)
- Drug Resistance, Neoplasm
- Female
- Humans
- Liposomes
- Mice
- Mice, Nude
- Ovarian Neoplasms
(drug therapy)
- Platinum Compounds
(pharmacology)
- Topotecan
(therapeutic use)
- Tumor Burden
(drug effects)
- Xenograft Model Antitumor Assays
|